Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05477446
Other study ID # BRYY-IIT-LCYJ-2022-002
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date October 1, 2022
Est. completion date August 1, 2025

Study information

Verified date July 2022
Source Beijing Friendship Hospital
Contact ZHAO Wang, MD
Phone 86-63139862
Email wangzhao@ccmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis.


Description:

There are limited options for treatment of r/r langerhans cell histiocytosis. CD207 is expressed on the membrane surface of langerhans cells,and it is an ideal target for CAR-T. In this study, investigators will evaluate the safety and efficacy of CD207 targeted CAR- T cell therapy in patients with r/r langerhans cell histiocytosis. The primary goal is safety and efficiency assessment, including incidence and severity of adverse events and overall response rate.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 12
Est. completion date August 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 65 Years
Eligibility Inclusion Criteria: 1. Relapsed or refractory langerhans cell histiocytosis, defined as: 1) any relapse during standard chemotherapy; 2) not responding to standard chemotherapy; 3) not achieving CR after first cycle of second-line chemotherapy for relapsed langerhans cell histiocytosis; 2. 3-65 years old; 3. Expected survival time = 3 months; 4. ECOG performance status of 0 or 1 (age = 16 years) or Karnofsky performance status> 80 (age < 16 years) ; 5. With single or venous blood collection standards, and no other cell collection contraindications; 6. WBC = 2.5×10^9/L ,LY = 0.7×10^9/L,LY% =15%; 7. Serum creatinine = 2.0 mg/dl; 8. ALT/AST = 2.5 x ULN; 9. Total bilirubin = 2.0 mg/dl; 10. PT:INR<1.7, or PT is within 4s of the normal value; 11. Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: 1. Transduced CAR+ T lymphocytes<5%, or expansion <5 folds after stimulation with anti CD3/anti CD28 beads; 2. Pregnant or breasting-feeding women; 3. Active hepatitis B or hepatitis C infection; 4. Patients with HIV infection; 5. Uncontrolled active infection; 6. Use of systemic corticosteroid therapy; 7. Have received gene therapy, or any other CAR-T treatment; 8. Allergic to immunotherapy and related drugs; 9. History of heart disease requiring treatment, or poorly controlled hypertension; 10. Preceding and/or ongoing active ulcer or gastrointestinal bleeding; 11. Have received allogeneic hematopoietic stem cell transplantation, or eligible for allogeneic hematopoietic stem cell transplantation; 12. Severe central nervous system involvement; 13. Severe lung involvement; 14. Hyponatremia (serum sodium<125mmol/L); 15. Hypokalemia (Serum kalium<3.5mmol/L); 16. Those who need long-term anticoagulation treatment (warfarin or heparin); 17. Those who need long-term antiplatelet treatment (aspirin, dose>300mg/d; clopidogrel, dose>75mg/d); 18. Radiation therapy within 4 weeks prior to registration; 19. Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina, cardiac arrhythmias, mental illness, and other diseases that in the opinion of the investigator would pose an unacceptable risk to the subject; 20. Have a history of severe allergy; 21. Current enrollment in another study; 22. Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement).

Study Design


Intervention

Biological:
CD207 CAR-T cells
Single dose of CD207 CAR-T cells administered IV

Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing

Sponsors (2)

Lead Sponsor Collaborator
Beijing Friendship Hospital Beijing Boren Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) The number of cases with complete response (CR) and partial response (PR) after treatment as a percentage of the total cases. 2 years
Primary Incidence and Severity of Adverse Events (AEs) Treatment-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) 2 years
Secondary Progression Free Survival (PFS) of CD207 CAR-T cell therapy in patients with r/r langerhans cell histiocytosis PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression. 2 years
Secondary Overall Survival (OS) of CD207 CAR-T cell therapy in patients with r/r langerhans cell histiocytosis OS will be assessed from the first CAR-T cell infusion to death from any cause. 2 years
Secondary Effects of CD207 CAR-T cells on human immune system Dynamic changes of T cell subset and immune globulin. 2 years
Secondary Metabolism of CAR T-cells in vivo Absorption, distribution and metabolism of CD207-CAR T cells in vivo. 2 years
See also
  Status Clinical Trial Phase
Completed NCT03270020 - Denosumab for the Treatment of Adult LCH Phase 2
Recruiting NCT05997602 - To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Completed NCT03096782 - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Phase 2
Recruiting NCT04120519 - Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis Phase 2
Recruiting NCT04121819 - AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis Phase 2
Recruiting NCT05284942 - Central China Rosai-Dorfman Disease Registry Phase 4
Active, not recruiting NCT03220035 - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT02608619 - Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Completed NCT01395004 - A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis Phase 2
Recruiting NCT02205762 - LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Phase 2/Phase 3
Active, not recruiting NCT02425904 - Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Phase 2
Recruiting NCT02670707 - Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Phase 3
Completed NCT02665546 - Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
Recruiting NCT04627090 - LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
Recruiting NCT03585686 - A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation Phase 2
Recruiting NCT03155620 - Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Phase 2
Recruiting NCT04773366 - A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol Phase 3
Completed NCT02389400 - Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis Phase 2
Completed NCT00588536 - Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH Phase 2